A Phase II, Double-Blind, Placebo-Controlled, Randomised, 6-Way Cross-Over, Single-Dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a beta-2-Agonist) Compared to Formoterol in Asthmatic Patients.

Trial Profile

A Phase II, Double-Blind, Placebo-Controlled, Randomised, 6-Way Cross-Over, Single-Dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a beta-2-Agonist) Compared to Formoterol in Asthmatic Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2014

At a glance

  • Drugs AZD 3199 (Primary) ; Formoterol
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Mar 2012 Results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 06 May 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top